Effectiveness of CRD-4730 in Participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Inclusion Criteria:

1. Males or Females ≥18 years of age, at screening.

2. Confirmed CPVT diagnosis, based on genetic screening for a known RyR2 mutation and aclinical phenotype consistent with CPVT at screening.

3. The participant can perform an EST during which frequent premature ventricularcontraction (PVCs) (≥10 per minute), ventricular bigeminy, or higher-grade VA (equivalent to a VA score ≥2) are identified by the investigator.

4. Stable doses of any anti-arrhythmic medication, except amiodarone, for 4 weeks priorto screening.

5. Adhere to all contraceptive criteria.

Exclusion Criteria:

1. Clinically significant structural heart disease, diagnosis of heart failure, orclinically significant coronary artery disease.

2. History of a myocardial infarction, cerebrovascular accident, or transient ischemicattack within 3 months of screening.

3. History of malignancy within the past 5 years at screening (except successfullytreated basal cell carcinoma or non-metastatic squamous cell carcinoma of the skinor cervical carcinoma in situ).

4. Female participant that is pregnant or lactating/ breastfeeding, or has plans to doso during the study or within 3 months following last dose of study drug.

5. Use of amiodarone with 3 months prior to screening. NOTE: other protocol definedInclusion/ Exclusion criteria may apply.